文章摘要
生 娣,杨 娜,谢 谦,时雯婷,许 玲.罗氟司特对脓毒症炎症大鼠炎症因子及淋巴细胞的调控机制分析[J].,2022,(14):2636-2641
罗氟司特对脓毒症炎症大鼠炎症因子及淋巴细胞的调控机制分析
Regulatory Mechanism of Roflumilast on Inflammatory Factors and Lymphocytes in Septic Inflammatory Rats
投稿时间:2022-01-07  修订日期:2022-01-30
DOI:10.13241/j.cnki.pmb.2022.14.007
中文关键词: 罗氟司特  JAK / STAT  脓毒症  miRNA-218
英文关键词: Roflumilast  JAK / STAT  Sepsis  miRNA-218
基金项目:新疆维吾尔自治区自然科学基金项目(2017d01c166)
作者单位E-mail
生 娣 新疆维吾尔自治区中医医院重症医学科 新疆 乌鲁木齐 830000 shengdi0020@163.com 
杨 娜 新疆维吾尔自治区中医医院高血压科 新疆 乌鲁木齐 830000  
谢 谦 新疆维吾尔自治区中医医院重症医学科 新疆 乌鲁木齐 830000  
时雯婷 新疆维吾尔自治区中医医院重症医学科 新疆 乌鲁木齐 830000  
许 玲 新疆维吾尔自治区中医医院重症医学科 新疆 乌鲁木齐 830000  
摘要点击次数: 715
全文下载次数: 417
中文摘要:
      摘要 目的:探究罗氟司特通过JAK/STAT途径对脓毒症炎症大鼠炎症因子及淋巴细胞的调控机制分析。方法:将54只SD大鼠随机分为正常组(n=18),模型组(n=18)和罗氟司特组(n=18),正常组正常喂养,模型组和罗氟司特组建立脓毒症大鼠模型。模型组和罗氟司特组腹膜内注射0.9 %的氯化钠和罗氟司特。干预7 d后,对大鼠取样。测定灌洗液中炎症细胞的数量、JAK和STAT-3的蛋白、AST和ALT、IL-6和TNF-α的mRNA表达。结果:在观察的7 d中,正常组大鼠均存活,生存率高于模型组和罗氟司特组(P<0.05),罗氟司特组生存率高于模型组(P<0.05)。与正常组相比,模型组和罗氟司特组术后症状评分均增加(P<0.05),罗氟司特组术后症状评分低于模型组(P<0.05)。模型组和罗氟司特组的miRNA-218表达低于正常组(P<0.05),而罗氟司特组高于模型组(P<0.05);模型组和罗氟司特组淋巴细胞,中性粒细胞和单核细胞总数,JAK和STAT-3的蛋白质表达,AST、ALT、IL-6和TNF-α水平高于正常组(P<0.05),罗氟司特组上述指标低于模型组(P<0.05)。结论:罗氟司特通过JAK / STAT途径阻断miRNA-218表达,抑制促炎性细胞因子IL-6和TNF-α的表达,减轻脓毒症炎症的机制和肝脏损害并改善多发性脓毒症的生存率。
英文摘要:
      ABSTRACT Objective: To explore the regulation mechanism of roflumilast on inflammatory factors and lymphocytes in septic inflammatory rats through JAK/STAT pathway. Methods: 54 SD mice were randomly divided into normal group (n = 18), model group (n = 18) and roflumilast group (n=18). The normal group was fed normally, and the model group and roflumilast group were used to establish sepsis model. In the model group and roflumilast group, 0.9% sodium chloride and roflumilast were injected intraperitoneally. After 7 days of intervention, the mice were sampled. The number of inflammatory cells, Jak and Stat-3 protein, AST and alt, IL-6 and TNF-α mRNA expression were measured. Results: The survival rate of normal group was higher than that of model group and roflumilast group (P<0.05). The survival rate of roflumilast group was higher than that of model group (P<0.05). Compared with the normal group, the postoperative symptom scores of the model group and the roflumilast group were increased (P<0.05), and the postoperative symptom score of the roflumilast group was lower than that of the model group (P<0.05). The expression of mirna-218 in model group and roflumilast group was lower than that in normal group (P<0.05), while that in roflumilast group was higher than that in model group (P<0.05). The total number of lymphocytes, neutrophils and monocytes, the protein expression of JAK and Stat-3, the levels of AST, alt, IL-6 and TNF-α in model group and roflumilast group were higher than those in normal group (P<0.05). The above indexes in roflumilast group were lower than those in model group (P<0.05). Conclusion: Roflumilast blocks the expression of miRNA-218 through the JAK/STAT pathway, inhibits the expression of pro-inflammatory cytokines IL-6 and TNF-α, reduces the mechanism of sepsis inflammation and liver damage, and improves the development of multiple sepsis survival rate.
查看全文   查看/发表评论  下载PDF阅读器
关闭